436 related articles for article (PubMed ID: 29614676)
1. Regional Distribution, Asymmetry, and Clinical Correlates of Tau Uptake on [18F]AV-1451 PET in Atypical Alzheimer's Disease.
Tetzloff KA; Graff-Radford J; Martin PR; Tosakulwong N; Machulda MM; Duffy JR; Clark HM; Senjem ML; Schwarz CG; Spychalla AJ; Drubach DA; Jack CR; Lowe VJ; Josephs KA; Whitwell JL
J Alzheimers Dis; 2018; 62(4):1713-1724. PubMed ID: 29614676
[TBL] [Abstract][Full Text] [Related]
2. Tau PET imaging predicts cognition in atypical variants of Alzheimer's disease.
Phillips JS; Das SR; McMillan CT; Irwin DJ; Roll EE; Da Re F; Nasrallah IM; Wolk DA; Grossman M
Hum Brain Mapp; 2018 Feb; 39(2):691-708. PubMed ID: 29105977
[TBL] [Abstract][Full Text] [Related]
3. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
[TBL] [Abstract][Full Text] [Related]
4. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
[TBL] [Abstract][Full Text] [Related]
5. Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech.
Utianski RL; Whitwell JL; Schwarz CG; Senjem ML; Tosakulwong N; Duffy JR; Clark HM; Machulda MM; Petersen RC; Jack CR; Lowe VJ; Josephs KA
Cortex; 2018 Feb; 99():358-374. PubMed ID: 29353121
[TBL] [Abstract][Full Text] [Related]
6. Association of
La Joie R; Visani AV; Lesman-Segev OH; Baker SL; Edwards L; Iaccarino L; Soleimani-Meigooni DN; Mellinger T; Janabi M; Miller ZA; Perry DC; Pham J; Strom A; Gorno-Tempini ML; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
Neurology; 2021 Feb; 96(5):e650-e661. PubMed ID: 33262228
[TBL] [Abstract][Full Text] [Related]
7. Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease.
Whitwell JL; Graff-Radford J; Tosakulwong N; Weigand SD; Machulda MM; Senjem ML; Spychalla AJ; Vemuri P; Jones DT; Drubach DA; Knopman DS; Boeve BF; Ertekin-Taner N; Petersen RC; Lowe VJ; Jack CR; Josephs KA
Alzheimers Dement; 2018 Aug; 14(8):1005-1014. PubMed ID: 29605222
[TBL] [Abstract][Full Text] [Related]
8. Visual cognition in non-amnestic Alzheimer's disease: Relations to tau, amyloid, and cortical atrophy.
Putcha D; Brickhouse M; Touroutoglou A; Collins JA; Quimby M; Wong B; Eldaief M; Schultz A; El Fakhri G; Johnson K; Dickerson BC; McGinnis SM
Neuroimage Clin; 2019; 23():101889. PubMed ID: 31200149
[TBL] [Abstract][Full Text] [Related]
9. Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease.
Xia C; Makaretz SJ; Caso C; McGinnis S; Gomperts SN; Sepulcre J; Gomez-Isla T; Hyman BT; Schultz A; Vasdev N; Johnson KA; Dickerson BC
JAMA Neurol; 2017 Apr; 74(4):427-436. PubMed ID: 28241163
[TBL] [Abstract][Full Text] [Related]
10. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
11. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy.
Passamonti L; Vázquez Rodríguez P; Hong YT; Allinson KS; Williamson D; Borchert RJ; Sami S; Cope TE; Bevan-Jones WR; Jones PS; Arnold R; Surendranathan A; Mak E; Su L; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB
Brain; 2017 Mar; 140(3):781-791. PubMed ID: 28122879
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease.
Sintini I; Martin PR; Graff-Radford J; Senjem ML; Schwarz CG; Machulda MM; Spychalla AJ; Drubach DA; Knopman DS; Petersen RC; Lowe VJ; Jack CR; Josephs KA; Whitwell JL
Neuroimage Clin; 2019; 23():101823. PubMed ID: 31004914
[TBL] [Abstract][Full Text] [Related]
13. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.
Maass A; Landau S; Baker SL; Horng A; Lockhart SN; La Joie R; Rabinovici GD; Jagust WJ;
Neuroimage; 2017 Aug; 157():448-463. PubMed ID: 28587897
[TBL] [Abstract][Full Text] [Related]
14. Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy.
Whitwell JL; Ahlskog JE; Tosakulwong N; Senjem ML; Spychalla AJ; Petersen RC; Jack CR; Lowe VJ; Josephs KA
Parkinsonism Relat Disord; 2018 Mar; 48():3-9. PubMed ID: 29254665
[TBL] [Abstract][Full Text] [Related]
15. Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease.
Sintini I; Schwarz CG; Martin PR; Graff-Radford J; Machulda MM; Senjem ML; Reid RI; Spychalla AJ; Drubach DA; Lowe VJ; Jack CR; Josephs KA; Whitwell JL
Hum Brain Mapp; 2019 Apr; 40(5):1618-1631. PubMed ID: 30549156
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal and cross-sectional structural magnetic resonance imaging correlates of AV-1451 uptake.
Das SR; Xie L; Wisse LEM; Ittyerah R; Tustison NJ; Dickerson BC; Yushkevich PA; Wolk DA;
Neurobiol Aging; 2018 Jun; 66():49-58. PubMed ID: 29518752
[TBL] [Abstract][Full Text] [Related]
17. AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies.
Kantarci K; Lowe VJ; Boeve BF; Senjem ML; Tosakulwong N; Lesnick TG; Spychalla AJ; Gunter JL; Fields JA; Graff-Radford J; Ferman TJ; Jones DT; Murray ME; Knopman DS; Jack CR; Petersen RC
Ann Neurol; 2017 Jan; 81(1):58-67. PubMed ID: 27863444
[TBL] [Abstract][Full Text] [Related]
18. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.
Schwarz AJ; Yu P; Miller BB; Shcherbinin S; Dickson J; Navitsky M; Joshi AD; Devous MD; Mintun MS
Brain; 2016 May; 139(Pt 5):1539-50. PubMed ID: 26936940
[TBL] [Abstract][Full Text] [Related]
19. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimer's Disease.
Louwersheimer E; Keulen MA; Steenwijk MD; Wattjes MP; Jiskoot LC; Vrenken H; Teunissen CE; van Berckel BN; van der Flier WM; Scheltens P; van Swieten JC; Pijnenburg YA
J Alzheimers Dis; 2016; 51(2):581-90. PubMed ID: 26890751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
